A Phase 1b/2a, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Subjects with Severe Sepsis
Tidswell, Mark, MD
Baystate Medical Center 759 Chestnut Street Springfield, MA 01199
The purpose of this study is to evaluate the safety and potential efficacy signal of the study drug, BMS-936559, in subjects with severe sepsis.
Eligible participants must be at least 18 years of age with proven or suspected infection as well as septic shock.